Late‑breaking results from the Majestec‑3 trial showed the teclistamab plus daratumumab combination produced an 83.4% three‑year progression‑free survival (PFS) rate versus 29.7% for standard care, data presented at ASH and reported by clinical investigators including Maria‑Victoria Mateos. Investigators described a dramatic reduction in progression or death with a plateau in PFS and overall survival curves, prompting discussion of “functional cure” potential. The readout comes amid a broader flurry of hematology data at ASH where J&J, Gilead and other firms disclosed competitive bispecific and CAR‑T results. Industry sources told meeting reporters the data set up direct commercial and clinical competition between off‑the‑shelf bispecifics and autologous or allogeneic CAR‑T approaches. Sponsors will now weigh comparative trials, sequencing strategies and real‑world access as they plan label expansions. Several companies disclosed complementary MM data at ASH that signal accelerating change in relapse‑line standards of care; payers and health systems will be watching durability, safety and cost as adoption debates move from conference halls to procurement committees.